巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Merck & Co

    MRK
    88.400
    0.810
    0.92%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Merck & Co - 延遲價格・最後更新於 04/10 12:00
    最高位
    88.640
    最低位
    87.000
    開市價
    --
    前收市價
    87.590
    成交量(千)
    548.15
    成交額(百萬)
    411.93
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    223,941.94
    市盈率
    13.500
    息率
    3.15%
    差價
    --
    52週高低
    95.720 - 71.500
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Merck & Co
    證券代碼
    MRK.US
    所屬板塊
    Drug Manufacturers - General
    公司業務
    Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
    發行量
    2528805025
    公司總部
    2000 Galloping Hill Road
    公司網址
    https://www.merck.com
    公司電郵
    investor_relations@merck.com
    公司電話
    +1 908 740-4000

    默沙東與國藥集團就抗新冠病毒口服藥物在華達成合作框架協議

    格隆匯·
    默沙東與國藥集團就抗新冠病毒口服藥物在華達成合作框架協議

    美國流行糖尿病藥物被發現含有潛在致癌物質,但仍將被准許銷售

    格隆匯·
    美國流行糖尿病藥物被發現含有潛在致癌物質,但仍將被准許銷售

    默克(MRK.US)Q2營收增長14.3%超預期 預計外匯正面影響加強 提高全年業績指引

    格隆匯··精選
    默克(MRK.US)Q2營收增長14.3%超預期 預計外匯正面影響加強 提高全年業績指引

    默克(MRK.US)Q2營收增長14.3%超預期 預計外匯正面影響加強 提高全年業績指引

    格隆匯·
    默克(MRK.US)Q2營收增長14.3%超預期 預計外匯正面影響加強 提高全年業績指引

    關於

    Merck & Co(MRK.US)所屬的行業板塊為Drug Manufacturers - General。
    Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
    截至04/10 12:00:00,Merck & Co的股價升0.92,市值223,941.94百萬。Merck & Co的市盈率及息率分別為13.500及3.15%。
    詳細公司背景可參考: https://www.merck.com